Telehealth palliative care and digital symptom monitoring for acute myeloid leukemia patients
The Feasibility of Telehealth-Based Palliative Care Intervention and Digital Symptom Monitoring on Patients With AML Receiving Low-Intensity Induction Therapy
This study is testing a new online support program for people recently diagnosed with acute myeloid leukemia to see if it helps them manage their symptoms better while they receive low-intensity treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Stanford University Academic / other |
| Locations | 1 site (Palo Alto, California) |
| Trial ID | NCT04885127 on ClinicalTrials.gov |
What this trial studies
This study evaluates the feasibility of a virtual supportive care model that combines early specialty palliative care referrals via telehealth with digital symptom monitoring for patients recently diagnosed with acute myeloid leukemia (AML) undergoing low-intensity therapy. The approach aims to improve symptom management and overall patient support by utilizing electronic patient-reported outcomes (PROs). The trial is a single-center, single-arm design conducted at Stanford Cancer Center, focusing on patients who are candidates for low-intensity induction therapy.
Who should consider this trial
Good fit: Ideal candidates are patients diagnosed with acute myeloid leukemia who are starting low-intensity induction therapy and have access to digital devices for symptom tracking.
Not a fit: Patients with relapsed or refractory AML or those who have previously established palliative care may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could enhance the quality of life and symptom management for patients with acute myeloid leukemia.
How similar studies have performed: While the benefits of early palliative care and electronic PROs have been established in oncology, this specific combination in the AML population is novel and has not been previously studied.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients being treated for a diagnosis of acute myeloid leukemia at Stanford Cancer Center * Patients determined to be candidates for low intensity induction therapy (not requiring hospitalization to administer treatment) by their leukemia physician * Estimated life expectancy of 6 months * Functional status at the level of at least being capable of limited self-care, confined to chair or bed for half the day or better * Access to smartphone, tablet, or computer with capability to utilize a symptom tracking application Exclusion Criteria: * Relapsed or refractory AML * Patients who have established care with palliative care previously * Non-English-speaking, as the Noona application is developed in the English language
Where this trial is running
Palo Alto, California
- Stanford University — Palo Alto, California, United States (Recruiting)
Study contacts
- Principal investigator: Gabriel Mannis, MD — Stanford University
- Study coordinator: Irena Tan, MD
- Email: irenatan@stanford.edu
- Phone: 650-498-6000
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.